Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1974 1
1975 2
1976 4
1977 4
1978 3
1979 3
1980 4
1981 3
1982 4
1983 10
1984 10
1985 10
1986 4
1987 3
1988 11
1989 5
1990 7
1991 4
1992 9
1993 12
1994 11
1995 16
1996 22
1997 15
1998 37
1999 43
2000 36
2001 44
2002 43
2003 61
2004 94
2005 87
2006 105
2007 143
2008 163
2009 164
2010 150
2011 181
2012 195
2013 244
2014 303
2015 338
2016 344
2017 344
2018 335
2019 366
2020 506
2021 558
2022 513
2023 425
2024 159

Text availability

Article attribute

Article type

Publication date

Search Results

5,100 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Age related macular degeneration 5"
Page 1
The Diagnosis and Treatment of Age-Related Macular Degeneration.
Stahl A. Stahl A. Dtsch Arztebl Int. 2020 Jul 20;117(29-30):513-520. doi: 10.3238/arztebl.2020.0513. Dtsch Arztebl Int. 2020. PMID: 33087239 Free PMC article. Review.
BACKGROUND: Age-related macular degeneration (AMD) is thought to cause approximately 9% of all cases of blindness worldwide. ...The early stage is often asymptomatic; patients in the other two stages often have distorted vision or central visual field …
BACKGROUND: Age-related macular degeneration (AMD) is thought to cause approximately 9% of all cases of blindnes …
Age-Related Macular Degeneration: A Review.
Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Fleckenstein M, et al. JAMA. 2024 Jan 9;331(2):147-157. doi: 10.1001/jama.2023.26074. JAMA. 2024. PMID: 38193957 Review.
IMPORTANCE: Age-related macular degeneration (AMD) affects approximately 20 million people in the US and 196 million people worldwide. AMD is a leading cause of severe vision impairment in older people and is expected to affect approximately 288 millio …
IMPORTANCE: Age-related macular degeneration (AMD) affects approximately 20 million people in the US and 196 mil …
Clinical classification of age-related macular degeneration.
Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR; Beckman Initiative for Macular Research Classification Committee. Ferris FL 3rd, et al. Ophthalmology. 2013 Apr;120(4):844-51. doi: 10.1016/j.ophtha.2012.10.036. Epub 2013 Jan 16. Ophthalmology. 2013. PMID: 23332590
OBJECTIVE: To develop a clinical classification system for age-related macular degeneration (AMD). DESIGN: Evidence-based investigation, using a modified Delphi process. ...RESULTS: Consensus was achieved in generating a basic clinical classification s …
OBJECTIVE: To develop a clinical classification system for age-related macular degeneration (AMD). DESIGN: Evide …
Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration.
Matsumoto H, Hoshino J, Nakamura K, Nagashima T, Akiyama H. Matsumoto H, et al. Graefes Arch Clin Exp Ophthalmol. 2023 Oct;261(10):2945-2952. doi: 10.1007/s00417-023-06116-y. Epub 2023 May 17. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 37195339
PURPOSE: To investigate the efficacy and safety of loading phase treatment with 3 monthly intravitreal injections of faricimab for neovascular age-related macular degeneration (nAMD). METHODS: We retrospectively analyzed 16-week outcomes of 40 consecut …
PURPOSE: To investigate the efficacy and safety of loading phase treatment with 3 monthly intravitreal injections of faricimab for neovascul …
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
Mori R, Honda S, Gomi F, Tsujikawa A, Koizumi H, Ochi H, Ohsawa S, Okada AA; TENAYA and LUCERNE Investigators. Mori R, et al. Jpn J Ophthalmol. 2023 May;67(3):301-310. doi: 10.1007/s10384-023-00985-w. Epub 2023 Apr 11. Jpn J Ophthalmol. 2023. PMID: 37039948 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the 1-year efficacy, durability, and safety of faricimab versus aflibercept in patients with neovascular age-related macular degeneration (nAMD) enrolled in the Japan subgroup of the TENAYA trial. ...The adjusted mean (95% confiden …
PURPOSE: To evaluate the 1-year efficacy, durability, and safety of faricimab versus aflibercept in patients with neovascular age- …
Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography.
Waldstein SM, Vogl WD, Bogunovic H, Sadeghipour A, Riedl S, Schmidt-Erfurth U. Waldstein SM, et al. JAMA Ophthalmol. 2020 Jul 1;138(7):740-747. doi: 10.1001/jamaophthalmol.2020.1376. JAMA Ophthalmol. 2020. PMID: 32379287 Free PMC article. Clinical Trial.
IMPORTANCE: The morphologic changes and their pathognomonic distribution in progressing age-related macular degeneration (AMD) are not well understood. OBJECTIVES: To characterize the pathognomonic distribution and time course of morphologic patterns i …
IMPORTANCE: The morphologic changes and their pathognomonic distribution in progressing age-related macular degenera …
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, Yamamoto A, Mukai R, Honjyo J, Maruko I, Kawai M, Miyara Y, Terao N, Wakatsuki Y, Onoe H, Mori R, Koizumi H, Sekiryu T, Iida T, Okada AA; for Japan AMD Research Consortium (JARC). Kataoka K, et al. Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):43-51. doi: 10.1007/s00417-023-06222-x. Epub 2023 Sep 5. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37668741
PURPOSE: To assess 6-month outcomes of switching from aflibercept to faricimab in eyes with refractory neovascular age-related macular degeneration (nAMD) previously requiring monthly injections. ...BCVA and maximal PED height showed no significant cha …
PURPOSE: To assess 6-month outcomes of switching from aflibercept to faricimab in eyes with refractory neovascular age-related …
Exudative non-neovascular age-related macular degeneration.
Bacci T, Essilfie JO, Leong BCS, Freund KB. Bacci T, et al. Graefes Arch Clin Exp Ophthalmol. 2021 May;259(5):1123-1134. doi: 10.1007/s00417-020-05021-y. Epub 2020 Nov 26. Graefes Arch Clin Exp Ophthalmol. 2021. PMID: 33242167
PURPOSE: To describe the clinical and multimodal imaging (MMI) features of age-related macular degeneration (AMD) eyes presenting with intraretinal exudation and no evidence of neovascularization or structural alterations of native retinal vessels. MET …
PURPOSE: To describe the clinical and multimodal imaging (MMI) features of age-related macular degeneration (AMD …
LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System.
Boyer D, Hu A, Warrow D, Xavier S, Gonzalez V, Lad E, Rosen RB, Do D, Schneiderman T, Ho A, Munk MR, Jaffe G, Tedford SE, Croissant CL, Walker M, Rückert R, Tedford CE. Boyer D, et al. Retina. 2024 Mar 1;44(3):487-497. doi: 10.1097/IAE.0000000000003980. Retina. 2024. PMID: 37972955 Free PMC article. Clinical Trial.
PURPOSE: The LIGHTSITE III study evaluated multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) age-related macular degeneration (AMD) using the LumiThera Valeda Light Delivery System. ...LIGHTSITE III met the primary efficacy best-co …
PURPOSE: The LIGHTSITE III study evaluated multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) age-related …
Age-Related Macular Degeneration: Genetics and Biology.
Kumaramanickavel G. Kumaramanickavel G. Asia Pac J Ophthalmol (Phila). 2016 Jul-Aug;5(4):229-35. doi: 10.1097/APO.0000000000000223. Asia Pac J Ophthalmol (Phila). 2016. PMID: 27488064 Free article. Review.
Age-related macular degeneration (AMD), widely prevalent across the globe, is a major stakeholder among adult visual morbidity and blindness, not only in the Western world but also in Asia. ...The noteworthy genetic variants (common and rare) are compl …
Age-related macular degeneration (AMD), widely prevalent across the globe, is a major stakeholder among adult vi …
5,100 results